.png)
.png)
UK biotech investment increases amidst progress in City of London to unlock new capital
The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, as revealed by new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of capital in the City of London.
BIA is first occupier at Victoria House, London’s life sciences hub
Oxford and Pioneer Group launch plans for central London's largest office-to-life sciences conversion project, securing first lease with BIA.
BIA joins UK Health Data Research Alliance
The BioIndustry Association (BIA) joins the UK Health Data Research Alliance as a member, alongside UK national data custodians, NHS foundation trusts and research institutes to help develop best practice around the ethical use of health data.
Pensions industry commitment to unlock investment welcomed by biotech leaders
Life science leaders applaud new initiatives to unlock pension fund assets for investment in the sector.
Boost UK manufacturing for £15 billion new investment, says medicines manufacturing alliance
The UK’s position as a manufacturing leader has declined, and a formerly strong trade balance has become a deficit, with medicine exports falling from almost $37 billion in 2015 to $25 billion in 2020.
BIA calls on government to support an attractive UK commercial environment for medicines
BIA has today published a report calling for the next Voluntary Pricing and Access Scheme (VPAS) to build on the spirit of partnership between government and life sciences industry seen during the COVID-19 pandemic.
BIA welcomes Chancellor’s life sciences growth package
The UK Government has announced a package of investment and policy initiatives to support the continued growth of the sector.
BIA launches #BIGIMPACT campaign to encourage talent with digital skills to start a career in biotech
The BioIndustry Association (BIA) is launching #BIGIMPACT, a new campaign encouraging people with digital and data-driven skills to consider a career in the biotech industry. The campaign shines a spotlight on new career pathways that are possible in biotech, for example, an AI engineer, bioinformatician or data analyst.
Venture deals continue to flow for UK biotech under dark clouds
The first quarter of 2023 has seen deal flow continue for the UK’s innovative life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence, venture investment remained steady, with private UK biotechs securing £258 million across 20 deals, with an average deal size of £13 million.
BIA calls on NICE to refresh evidence informing how rare disease medicines are evaluated and paid for
The UK BioIndustry Association has today published research suggesting the UK’s medicines evaluation body is basing its methods and processes for evaluating medicines for rare diseases on outdated evidence. Rare insights: examining the social values of treating rare diseases presents the findings of primary research into public opinion on how treatments for rare diseases should be evaluated and funded within the NHS.
